Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project.
Authors
Letovanec, IFinn, S
Zygoura, P
Smyth, P
Soltermann, A
Bubendorf, L
Speel, E
Marchetti, A
Nonaka, Daisuke
Monkhorst, K
Hager, H
Martorell, M
Sejda, A
Cheney, R
Hernandez-Losa, J
Verbeken, E
Weder, W
Savic, S
Di Lorito, A
Navarro, A
Felip, E
Warth, A
Baas, P
Meldgaard, P
Blackhall, Fiona H
Dingemans, A
Dienemann, H
Dziadziuszko, R
Vansteenkiste, J
O'Brien, C
Geiger, T
Sherlock, J
Schageman, J
Dafni, U
Kammler, R
Kerr, K
Thunnissen, E
Stahel, R
Peters, S
Affiliation
Institute of Pathology, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, SwitzerlandIssue Date
2017-11-27
Metadata
Show full item recordAbstract
The reported prevalence of ALK rearrangement in NSCLC ranges from 2%-7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) has also proven to be a reproducible and sensitive technique. Reverse transcriptase-polymerase chain reaction (RT-PCR) has also been advocated and most recently the advent of targeted Next-Generation Sequencing (NGS) for ALK and other fusions has become possible. This study compares ALK evaluation with all 4 techniques in resected NSCLC from the large ETOP Lungscape cohort.Citation
Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project. 2017 J Thorac OncolJournal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2017.11.117PubMed ID
29191776Type
ArticleLanguage
enISSN
1556-1380ae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2017.11.117
Scopus Count
Collections
Related articles
- Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
- Authors: Kuang Y, Xu P, Wang J, Zheng Y, Sun X, Li Z, Gan R, Li H, Guo Y, Yao F, Zhu C, Ke Z, Tang K
- Issue date: 2021 Jul
- Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
- Authors: Wang B, Chen R, Wang C, Guo J, Yuan M, Chen H, Xia X, Zhong D
- Issue date: 2021 Aug
- Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
- Authors: Xu CW, Wang WX, Chen YP, Chen Y, Liu W, Zhong LH, Chen FF, Zhuang W, Song ZB, Chen XH, Huang YJ, Guan YF, Yi X, Lv TF, Zhu WF, Lu JP, Wang XJ, Shi Y, Lin XD, Chen G, Song Y
- Issue date: 2018 Apr 11
- Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
- Authors: Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA
- Issue date: 2014 Sep 1
- Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
- Authors: Marchetti A, Pace MV, Di Lorito A, Canarecci S, Felicioni L, D'Antuono T, Liberatore M, Filice G, Guetti L, Mucilli F, Buttitta F
- Issue date: 2016 Sep